Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 5/20 | 0.48 |
| ▸ | CA9 | Q16790 | 5/20 | 0.48 |
| ▸ | CA12 | O43570 | 4/20 | 0.48 |
| ▸ | CA1 | P00915 | 4/20 | 0.48 |
| ▸ | MMP12 | P39900 | 2/20 | 0.46 |
| ▸ | MMP9 | P14780 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18241575 | 1.00 | LMNA (0.64) | LMNAKMT2APOLBALDH1A1CYP3A4 | |
| SCHEMBL19772702 | 1.00 | LMNA (0.64) | LMNAKMT2APOLBALDH1A1CYP3A4 | |
| SCHEMBL17235369 | 1.00 | LMNA (0.64) | LMNAKMT2APOLBALDH1A1CYP3A4 | |
| SCHEMBL20348905 | 1.00 | LMNA (0.64) | LMNAKMT2APOLBALDH1A1CYP3A4 | |
| SCHEMBL18972833 | 1.00 | LMNA (0.64) | LMNAKMT2APOLBALDH1A1CYP3A4 | |
| SCHEMBL24807806 | 1.00 | LMNA (0.64) | LMNAKMT2APOLBALDH1A1CYP3A4 | |
| SCHEMBL19572694 | 1.00 | LMNA (0.64) | LMNAKMT2APOLBALDH1A1CYP3A4 | |
| SCHEMBL18513238 | 1.00 | LMNA (0.64) | LMNAKMT2APOLBALDH1A1CYP3A4 | |
| SCHEMBL22927913 | 1.00 | LMNA (0.64) | LMNAKMT2APOLBALDH1A1CYP3A4 | |
| SCHEMBL26707084 | 1.00 | LMNA (0.64) | LMNAKMT2APOLBALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230355775-A1 | NUCLEIC ACID, COMPOSITION AND CONJUGATE CONTAINING SAME, PREPARATION METHOD, AND USE THEREOF | Suzhou Ribo Life Science Co., Ltd. (CN) | 2023-11-09 | — | — | US | disclosed |
| US-20230313195-A1 | NUCLEIC ACID, PHARMACEUTICAL COMPOSITION, CONJUGATE, PREPARATION METHOD, AND USE | Suzhou Ribo Life Science Co., Ltd. (CN) | 2023-10-05 | — | — | US | disclosed |
| EP-4223315-A2 | METHOD FOR SYNTHESIS OF REACTIVE CONJUGATE CLUSTERS | Ionis Pharmaceuticals, Inc. (US) | 2023-08-09 | — | — | EP | disclosed |
| US-20230193277-A1 | NUCLEIC ACID, PHARMACEUTICAL COMPOSITION, CONJUGATE, PREPARATION METHOD, AND USE | Suzhou Ribo Life Science Co., Ltd. (CN) | 2023-06-22 | — | — | US | disclosed |
| US-11660347-B2 | Nucleic acid, composition and conjugate containing same, preparation method, and use thereof | Suzhou Ribo Life Science Co., Ltd. (CN) | 2023-05-30 | — | — | US | disclosed |
| US-20230159929-A1 | MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) MOLECULES AND USES THEREOF | ALIGOS THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-11649260-B2 | Functionalized N-acetylgalactosamine nucleosides | HONGENE BIOTECH CORPORATION (US) | 2023-05-16 | — | — | US | disclosed |
| US-20230138928-A1 | 1'-ALKYL MODIFIED RIBOSE DERIVATIVES AND METHODS OF USE | SANEGENE BIO USA INC. | 2023-05-04 | — | — | US | disclosed |
| WO-2023016999-A2 | Compounds | Cargene Therapeutics Pte. Ltd. (SG) | 2023-02-16 | — | — | WO | disclosed |
| US-20220395526-A1 | NUCLEIC ACID, COMPOSITION AND CONJUGATE CONTAINING SAME, AND PREPARATION METHOD AND USE | Suzhou Ribo Life Science Co., Ltd. (CN) | 2022-12-15 | — | — | US | disclosed |
| US-9994855-B2 | Compositions and methods for modulating growth hormone receptor expression | IONIS PHARMACEUTICALS, INC. (US) | 2018-06-12 | — | — | US | disclosed |
| US-20170166899-A1 | COMPOSITIONS AND METHODS FOR MODULATING GROWTH HORMONE RECEPTOR EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2017-06-15 | — | — | US | disclosed |
| US-20170095493-A1 | NOVEL TLR4 INHIBITORS FOR THE TREATMENT OF HUMAN INFECTIOUS AND INFLAMMATORY DISORDERS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2017-04-06 | — | — | US | disclosed |
| US-20170043025-A1 | METHOD FOR SYNTHESIS OF REACTIVE CONJUGATE CLUSTERS | IONIS PHARMACEUTICALS, INC. (US) | 2017-02-16 | — | — | US | disclosed |
| US-9532999-B2 | TLR4 inhibitors for the treatment of human infectious and inflammatory disorders | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2017-01-03 | — | — | US | disclosed |
| US-9345781-B2 | Targeted dendrimer-drug conjugates | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2016-05-24 | — | — | US | disclosed |
| US-20150250809-A1 | NOVEL TLR4 INHIBITORS FOR THE TREATMENT OF HUMAN INFECTIOUS AND INFLAMMATORY DISORDERS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2015-09-10 | — | — | US | disclosed |
| US-9072760-B2 | TLR4 inhibitors for the treatment of human infectious and inflammatory disorders | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2015-07-07 | — | — | US | disclosed |
| WO-2015006740-A2 | OLIGONUCLEOTIDE-LIGAND CONJUGATES AND PROCESS FOR THEIR PREPARATION | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-01-15 | — | — | WO | disclosed |
| US-20130281395-A1 | NOVEL TLR4 INHIBITORS FOR THE TREATMENT OF HUMAN INFECTIOUS AND INFLAMMATORY DISORDERS | SYSTEM OF HIGHER EDUCATION UNIVERSITY OF PITTSBURGH OF THE COMMONWEALTH (US) | 2013-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159929-A1 | MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) MOLECULES AND USES THEREOF | SNRPA, SNRPA1, NSUN2 | LMNA 323/4885KMT2A 907/4885POLB 57/4885 |
| US-20150250809-A1 | NOVEL TLR4 INHIBITORS FOR THE TREATMENT OF HUMAN INFECTIOUS AND INFLAMMATORY DISORDERS | TLR4, TLR3, TLR1 | LMNA 3101/4885KMT2A 4485/4885POLB 4103/4885 |
| US-20220395526-A1 | NUCLEIC ACID, COMPOSITION AND CONJUGATE CONTAINING SAME, AND PREPARATION METHOD AND USE | NSUN2, RNGTT, ADAR | LMNA 856/4885KMT2A 645/4885POLB 25/4885 |
| US-11660347-B2 | Nucleic acid, composition and conjugate containing same, preparation method, and use thereof | APOB, C1QBP, APOL1 | LMNA 301/4885KMT2A 1671/4885POLB 184/4885 |
| US-20230193277-A1 | NUCLEIC ACID, PHARMACEUTICAL COMPOSITION, CONJUGATE, PREPARATION METHOD, AND USE | F13A1, F13B, F11 | LMNA 91/4885KMT2A 1302/4885POLB 195/4885 |
| US-20230355775-A1 | NUCLEIC ACID, COMPOSITION AND CONJUGATE CONTAINING SAME, PREPARATION METHOD, AND USE THEREOF | APOB, C1QBP, APOL1 | LMNA 301/4885KMT2A 1671/4885POLB 184/4885 |
| US-20170095493-A1 | NOVEL TLR4 INHIBITORS FOR THE TREATMENT OF HUMAN INFECTIOUS AND INFLAMMATORY DISORDERS | TLR4, TLR3, TLR1 | LMNA 3101/4885KMT2A 4485/4885POLB 4103/4885 |
| US-20130281395-A1 | NOVEL TLR4 INHIBITORS FOR THE TREATMENT OF HUMAN INFECTIOUS AND INFLAMMATORY DISORDERS | TLR4, TLR3, TLR1 | LMNA 3101/4885KMT2A 4485/4885POLB 4103/4885 |
| US-11649260-B2 | Functionalized N-acetylgalactosamine nucleosides | FUT6, B3GNT2, GALNT6 | LMNA 657/4885KMT2A 2894/4885POLB 853/4885 |
| US-20170043025-A1 | METHOD FOR SYNTHESIS OF REACTIVE CONJUGATE CLUSTERS | ACOT7, COASY, LCAT | LMNA 3182/4885KMT2A 849/4885POLB 1161/4885 |
| US-20230313195-A1 | NUCLEIC ACID, PHARMACEUTICAL COMPOSITION, CONJUGATE, PREPARATION METHOD, AND USE | PCSK9, PCSK7, PCSK6 | LMNA 56/4885KMT2A 321/4885POLB 84/4885 |
| US-20230138928-A1 | 1'-ALKYL MODIFIED RIBOSE DERIVATIVES AND METHODS OF USE | PARP1, PARP2, PARP11 | LMNA 191/4885KMT2A 1180/4885POLB 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.